Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Mayo Clinic

Status: Completed

Conditions: Eosinophilic Asthma

Study type: Observational

Funder types: Other

Identifiers

NCT05002621

20-005018

Details and patient eligibility

About

The purpose of this study is to identify gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA), and to determine the composition of immune cells present in the microenvironment of individuals with SEA after initiation of mepolizumab.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years old.
• Diagnosis of SEA by a health care provider
• History of an absolute eosinophil count ≥ 300/mm^3
• Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started

Exclusion criteria

• Age < 18 years old.
• Pregnancy.
• Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
• Currently using or any prior use of rituximab.
• History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
• Any prior history of malignancy, autoimmune disease, or immune deficiency.
• Any other significant medical issue as determined by the principal investigator.